Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Omega Therapeutics Presents New Preclinical Data Supporting The Potential Of Precision Epigenomic Control At AACR 2024

Author: Benzinga Newsdesk | April 09, 2024 07:06am
  • MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanism
  • Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller

Posted In: OMGA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist